Buradasınız

Anasayfa » Content

KRONİK HEMODIALIZ HASTALARINDA anti-HCV PREVALANSI

THE PREVALENCE OF ANTI-HCV IN CHRONIC HAEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
An enzyme immünoassay was used to detect antibodies to hepatitis C virus (anti-HCV) in patients in our hemodialysis unit. Tlie prevalence of anti-HCV an¬tibody in the group of 60patients was 48%. The prevalence of anti-HCV increased significantly with increasing duration of hemodialysis (p <0.01), number of blood transfusions (p<0.01 and seropozitivity of an-ti-HBc(p<0.01), but was not related to age, sex, hepatitis B status, or serum alanine aminotransferase (ALT) levels. Besides strict infection control measures, further studies are needed to determine the incidence of HCV infection and its prevention in the hemodialysis unit.
Bookmark/Search this post with
Abstract (Original Language): 
Hemodializ ünitemizdeki hastalarda anti-HCV antikorlarını tesbit etmek amacıyla enzim immünoassay testi uygulandı. 60 hastalık grupta anti-HCV prevalan-sı %48 idi. Anti-HCVprevalansı, artan hemodializ süresi (p<0.01), kan transfüzyonıı sayısı (p<0.01) ve an-ti-HBc seropozitifliği (p<0.01) ile ilişkili fakat yaş, cinsiyet, hepatit B durumu veya senim ALT seviyesi ile ilişkisiz bulundu. Bu nedenle, hemodializ ünitelerinde kesin infeksiyon kontrol uygulamaları yanında HCV infeksiyonunu tesbite ve korunmaya yönelik ileri çalışmalara ihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_37.pdf
  • 1
5-8
  • Turkish

REFERENCES

References: 

1. Hilfenhaus J, Krupha U, Nowak T, Cummins LB, Fuchs K, Roggendorf M. Follow-up of hepatitis C virus infection in chimpanzees: determination of viraemia and specific humoral mimune response. J Gen Virol 73:1015-1019,1992.
2. Shindo M, Di Bisceglie AM, Biswas R. Mihalik K. Feinstone SM: Hepatitis C virus replication during acute infection in the chimpanzee, J Infect Dis. 166(2):424-427,1992.
3. Takacs M. Berencsi G. Mezey I. Muranyine Brojnas J, Barcsay E. Ferenczi E. et al: Transfusion-associated non-A, non-B, non-C hepatitis caused by flaviviruses. Orv Hetil. 133
Suppl 1:37-39,1992.
4. Shirai M. Akatsuka T. Pendleton CD. Houghten R.
Wychowski C. Mihalik K. et al. Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstuctural
RNA polymerase-like protein. J Virol. 66(7):4098-4106,1992.
5. Fujiyama S. Kawano S. Sato S. Tanaka M. Goto M. Taura Y. et al: Prevalence of hepatitis C virus antibodies in hemodialysis patients and dialysis staff. Hepatogastroen-
terology. 39(2):161-165,1992.
6. Hies M. Szontagh L. Gal G: Hepatitis B virus markers and anti-HCV antibodies in hemodialyzed patinets. Orv Hetil. 133
Suppl 1:27-30,1992.
7. Nemeth J. Hejjas M. Buki B. Takacs M. Schaff Z. Mako J. et
al: Determination of hepatitis C antibodies, using the Abbott and the Ortho anti-HCV EIA kits, in chronic liver diseases and patents under hemodialysis for chronic renal failure. Orv
Hetil. 133 Suppl 1: 24-7,1992.
8. Hejjas M. Medgyesi G. Hajnal A: Reactivity of hepatitis C virus (HCV) antibody among blood donars in Hungary. Orv
Hetil. 133 Suppl 1:21-24,1992.
9. Rapicetta M. Attili AF. Mele A. De santis A. Chionne P. Cristiano K. et al: Prevalence of hepatitis C virus antibodies and hepatitis C virus-RNA in an urban population. J Med
Virol. 37(2):87-92,1992.
10. Lai JY. Tarn JS. Lam LY. Leung NW: Prevalence of antibody to hepatitis C virus in HB.Ag-negative chronic liver disease in Hong Kong using different assays. J Med Virol. 37(2): 158-160.1992.
11. Hyams KG Philips IA, Moran AY. Tejada A. Wignall FS.
7
Escamilla J: Seroprevalence of hepatitis C antibody in Peru. J Med Virol. 37(2): 127-131,1992.
12. Sheu JC. Lee SH. Wang JT. Shin LN. Wang TH. Chen DS: Prevalence of anti-HCV and HCV vircmia in hemodialysis
patients in Taiwan. J Med Virol. 37(2):108-112,1992.
13. Smith D. Delaney S. Allain JP. Vallari D. Lee H: A
comparison of two supplemental procedures for confirmation of antibody to hepatitis C virus clOO-3 antigen in Louisiana
blood donors. Transfusion. 32(5);415-419,1992.
14. Yap I. Guan R. Kang JY. Tay HH. Lee E. Choong L. et al:
Seroprevalence of antibodies to the hepatitis C virus in Singapore. Southeast Asian J Trop Med Public Health. 22(4):581-585,1991.
15. Leslie DE. Rann S. Nicholson S. Fairley CK. Gust ID:
Prevalence of hepatitis C antibodies in patients with clotting disorders in Victoria. Relationship with other blood borne
viruses and liver disease. Med J Aust. 156(11):789-792,1992.
16.
Arınso
y T. Arık N. Sungur C. Yasavul Ü. Turgan Ç. Çağlar Ş: Ilemodializ hastalarında hepatit C virus antikoru. XIX. Ulusal nefroloji kong. Kong.Kitabı.Kuşadası. 85,1990.
17. Par A: Antibody to hepatitis C virus in Hungary. Lancet. 336:123.1990.
18. Van Der Poel CL. Reesink HW.Lelie PN. Exel Oehlers P.
Winkel I. Schaasberg W. et al: Anti-HCV and transaminase
testing of blood donors. Lancet. 336:187-88,1990.
19.
Gill
i P. Moretti M. Soffritti S. Menini C: Anti-HCV positive
patients in dialysis units. Lancet 336:243-244,1990.
20. Wongs DC. Diwan AR. Rosen I. Gerin JL. Johnson RG. Polito A. et al: Non-specificity of anti-HCV test for seroepidemiological analysis. Lancet. 336;750-751,1990.
21. Vagelli G. Calabrese G. Guaschino R. Gonella M: Effect of HCV+patients isolation on HCV infection incidence in a
dialysis unit. Nephrol Dial Transplant. 7(10): 1070,1992.
22. Fest T. Viel JF. Agis F. Coffe C. Dupond JL. Herve P: Risk
factors associated with hepatitis B or C markes or elevated alanine aminotransferase level among blood donors on a tropical island: the Guadeloupe experience. Transfusion.
32(8): 760-763,1992.
23. Mathiesen UL. Ekermo B. Foberg U. Franzen L. Fryden A. Norlin R. et al: Anti-hepatitis C virus screening will reduce the incidence of post-tarnsfusion hepatitis C also in low-risk areas.
Scand J Gastroenterol. 27(6):443-448,1992.
24. Chen PJ. Wahg JT. Hwang LH. Yang YH. Hsieh CL. Kao JH.
et al: Transient immunoglobulin M antibody response to hepatitis C virus capsid antigen in posttransfusion hepatitis C: putative serological marker for acute viral infection. Proc Natl
Acad Sci USA. 89(13):5971-5975,1992.
25. Chou WH. Sheu L. Cheng SF. Sheu SH. Lu CF. Saito L et al:
Molecular cloning of cDNA of hepatitis C virus (HCV) genome from a healthy carrier in an aboriginal community in Taiwan with high prevalence of HCV infection.Jpn J Med Sci
Biol. 44(4): 147-157,1991.
26. Burt MJ. Hann DJ. Schousboe MI. Wilkinson ID. Chapman Ba: The prevalence of antibodies to hepatitis C virus in patents with chronic liver disease. NZ Med J. 105(934): 195-196,1992.
27. Zeldis JB;Depner TA; Kuramoto BS; Gish RG; Holland PV:
The prevalance of hepatitis C virus antibodies among
hemodialysis patients. An In Med. 112;958-960,1990.
28. Lin HH. Huang CC. Sheen IS. Lin DY. Liaw YF: Prevalence
of antibodies to hepatitis C virus in the hemodialysis unit. Am J Nephrol. 11(3):192-194,1991.
29. Mondelli MU. Christina G. Filice G. Rondanelli EG. Piazza.
V. Barbieri C: Anti-HCV positive patients in dialysis units.
Lancet. 336:244-245,1990.
30. Carrera F. Silva JG. Pires C. Oliveria C: Prevalnece of non-A non-B hepatitis and anti-HCV antibodies in a Portuguese dialysis population. Nephrol Dial Transplant. 7(9):913-916,1992.
31. Orak E. Karakullukçu F. Müderrisoğlu C: Hemodializ servisi hasta ve pesonelinde anti-HCV sıklığı: XIX. Ulusal nefroloji kong.Kong. Kitabı.Kuşadası.79,1990.
32. Bozfakioğlu S.Ark E. Ökten A. Aysuna N. Sever MS. Badur S.
et al: Hemodializ hastalarında anti-HCV prevalansı ve önemi.
XIX. Ulusal nefroloji kong.Kong.Kitabı.Kuşadası.79,1990.
33. Ataman R. Sonsuz A. Ayaz M. Dalmak S. Serdengeçti K. Erek E. et al: Hemodializ hastalarında anti-HCV prevalansı. XIX. Ulusal nefroloji kong.Kong. Kitabı: Kuşadası. 61,1990.
34. Ok E. Töz H. Yönetçi N. Başçı A. Batur Y. Çavuşoğlu H:
Hemodializ ünitesinde hepatit C virus antikorları prevalansı.
XIX. Ulusal nefroloji kon.Kong.Kitabı.Kuşadası.57,1990.
35. Akdiş C. Dilek K. Helvacı S. Mistik R. Güllülü M. Yavuz M.
et al: Kronik hemodiyaliz olgularında parentral buluşan viral enfeksiyonlar ile kan transfüzyon sayısı ve diyaliz süresi ilişkisi.
Türk Nefrol Dial ve Transp Derg. (2):83-87,1992.
36. Rochlani M. Lewis JH. Ramsmey GE. Bontempo FA. Shah G. Bowmann RA. et al: Hepatitis C tisting. Comparison of Ortho's EIA and RIBA II tests in 1,182 patients undergoing pirmary liver transplantation. Am J Clin Pathol. 98(1):8-12,1992.
37. Boudart D. Lucas JC. Muller JY. Carrer DL. Planchon B.
Harousseau JL: False-positive hepatitis C virus antibody tests in paraproteinemia. Lancet. 336:63,1990.
38. Aceti A. Taliani G. De Bac C. Sebastiani A:Anti-HCV false positivity in malaria. Lancet,336;1442-1443,1990.
39. Busch MP. Wilber JC. Johnson P. Tobler L. Evans CS: Impact
of specimen handling and storage on detection of hepatitis C
virus RNA. Tnasfusion. 32(5):420-425,1992.
40. Clewley JP: Detection of hepatitis C virus in serum. Lancet. 336:309-310,1990.
41. Laurent F. Li JS. Vitvitski L. Berby F. Lamelin JP. Alonso C. et al. Importance of PCR in the diagnosis of hepatitis C. Rew
FrTransfus Hemobiol. 35(3):211-224,1992.
42. Van Der Poel CL. Reesink HW. Cuypers HThM. Lelie PN.
Schaasberg W: Is anti-HCV blood donor screening useful.
Lancet. 336:1193,1990.
43. Donahue JG. Munoz A. Ness PM. Brown DE Jr. Yawn DH. McAllister HA Jr. et al: The declining risk of post-transfusion
hepatitis C virus infection. N Engl J Med. 327(6): 369-373,1992.
44. Ippolito E. Aterini S. Salvadori M. D'Elia D. Amato M: Do hemodialysed patients contribute to the spread of HCV
infection. Nephro. 62(2):248,1992.
8

Thank you for copying data from http://www.arastirmax.com